Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Assessing the impact of cytomegalovirus infection on prognosis and survival of aerodigestive tract cancers based on Ontario data
EF 2023-24
Résumé
Cytomegalovirus (CMV) infection is highly common around the world, and it's estimated that 25-65% of the Canadian population is infected. The immune system is unable to clear CMV and research shows this leaves individuals who already have compromised immune systems, such as people living with HIV and the elderly, at increased risk of death. Previous work shows that CMV infection in blood cancer patients can be associated with poor survival, but little work has focused on CMV infection in aerodigestive tract cancers (lung and head and neck (HNC) cancers). Due to the poor survival rate and heavy burden of aerodigestive tract cancers and the high rate of CMV infection amongst Canadians, research into CMV as it affects prognosis and survival is important to provide optimal patient management at the time of diagnosis.
My goal is to examine the effect of CMV infection on survival of patients with aerodigestive tract cancers. I will do this by examining how survival is impacted by CMV infection and by type of cancer (i.e., where cancer is located in the lung or head and neck).
To achieve these aims, epidemiological data, blood samples, and clinical outcomes data on lung and HNCs recruited from Princess Margaret Hospital will be used to evaluate the impact of CMV infection. I will then report 5-year and 10-year survival estimates and estimate how survival changes when cancer patients are infected with CMV.
I will be able to work with patient groups and clinical partners to better understand how my findings will affect patients and their families and work with clinical partners.
CMV is highly present within the population, but CMV is under-studied and public awareness is lacking. The results of my work have clinical actionability because it's possible to treat CMV with anti-viral therapy. With enough data on how CMV affects survival of aerodigestive tract cancer patients, we can screen patients for CMV infection at diagnosis and improve patient management strategies.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
496541
Name
Murison Kiera R
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Assessing the impact of cytomegalovirus infection on prognosis and survival of aerodigestive tract cancers based on Ontario data
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cytomegalovirus Infection; Head And Neck Cancer; Humans; Lung Cancer; Prognosis; Survival
Abstract
Cytomegalovirus (CMV) infection is highly common around the world, and it's estimated that 25-65% of the Canadian population is infected. The immune system is unable to clear CMV and research shows this leaves individuals who already have compromised immune systems, such as people living with HIV and the elderly, at increased risk of death. Previous work shows that CMV infection in blood cancer patients can be associated with poor survival, but little work has focused on CMV infection in aerodigestive tract cancers (lung and head and neck (HNC) cancers). Due to the poor survival rate and heavy burden of aerodigestive tract cancers and the high rate of CMV infection amongst Canadians, research into CMV as it affects prognosis and survival is important to provide optimal patient management at the time of diagnosis.
My goal is to examine the effect of CMV infection on survival of patients with aerodigestive tract cancers. I will do this by examining how survival is impacted by CMV infection and by type of cancer (i.e., where cancer is located in the lung or head and neck).
To achieve these aims, epidemiological data, blood samples, and clinical outcomes data on lung and HNCs recruited from Princess Margaret Hospital will be used to evaluate the impact of CMV infection. I will then report 5-year and 10-year survival estimates and estimate how survival changes when cancer patients are infected with CMV.
I will be able to work with patient groups and clinical partners to better understand how my findings will affect patients and their families and work with clinical partners.
CMV is highly present within the population, but CMV is under-studied and public awareness is lacking. The results of my work have clinical actionability because it's possible to treat CMV with anti-viral therapy. With enough data on how CMV affects survival of aerodigestive tract cancer patients, we can screen patients for CMV infection at diagnosis and improve patient management strategies.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Murison, Kiera R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~